Understanding and Tackling the Placebo Response in Parkinson's Disease


For conditions like Parkinson’s Disease, where subjective reporting measures are crucial, the placebo response poses a significant challenge. This issue leads to:

  • Increased development costs
  • Extended timelines
  • Premature abandonment of promising development programs

Ultimately, this results in a lack of effective treatments for patients suffering from parkinson's Disease.

In this guide, we explore:

  • The unique impact of the placebo problem on patients with parkinson's Disease
  • Historical methods for managing the placebo response in pain treatment
  • A new strategy aimed at successfully delivering a cure

Download the guide to learn more.

PD ebook

Download our eBook

  • This field is for validation purposes and should be left unchanged.

About Cognivia

Cognivia is the first and only company to combine behavioral science with artificial intelligence (AI)/machine learning (ML) to improve measurement of therapeutic efficacy in clinical trials – and beyond. Cognivia technologies predict patient behavior and treatment response in clinical trials using predictive ML powered algorithms based on a quantitative understanding of patient psychological traits, expectations and beliefs collected via our own and specific questionnaires developed toward that objective.

Cognivia aims at harnessing "the power of the mind" and quantifying this unique phenomenon to improve clinical trial success rates, de-risk drug development and ultimately improve healthcare.